116 related articles for article (PubMed ID: 16271760)
1. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias.
Inomata M; Takahashi S; Harigae H; Kameoka J; Kaku M; Sasaki T
Leuk Res; 2006 Jun; 30(6):659-64. PubMed ID: 16271760
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.
Takahashi S; Harigae H; Ishii KK; Inomata M; Fujiwara T; Yokoyama H; Ishizawa K; Kameoka J; Licht JD; Sasaki T; Kaku M
Leuk Res; 2005 Aug; 29(8):893-9. PubMed ID: 15978940
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice.
Hirouchi T; Takabatake T; Yoshida K; Nitta Y; Nakamura M; Tanaka S; Ichinohe K; Oghiso Y; Tanaka K
Exp Hematol; 2008 Jul; 36(7):871-85. PubMed ID: 18375040
[TBL] [Abstract][Full Text] [Related]
4. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
[TBL] [Abstract][Full Text] [Related]
5. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
[TBL] [Abstract][Full Text] [Related]
6. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
7. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
8. PU.1 and CEBPA expression in acute myeloid leukemia.
D'Alò F; Di Ruscio A; Guidi F; Fabiani E; Greco M; Rumi C; Hohaus S; Voso MT; Leone G
Leuk Res; 2008 Sep; 32(9):1448-53. PubMed ID: 18308386
[TBL] [Abstract][Full Text] [Related]
9. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
[TBL] [Abstract][Full Text] [Related]
10. PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.
Verbiest T; Bouffler S; Nutt SL; Badie C
Carcinogenesis; 2015 Apr; 36(4):413-9. PubMed ID: 25750172
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
12. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns.
Andersson A; Paulsson K; Lilljebjörn H; Lassen C; Strömbeck B; Heldrup J; Behrendtz M; Johansson B; Fioretos T
Genes Chromosomes Cancer; 2008 Jan; 47(1):64-70. PubMed ID: 17943971
[TBL] [Abstract][Full Text] [Related]
13. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
[TBL] [Abstract][Full Text] [Related]
14. Identification of annexin 1 as a PU.1 target gene in leukemia cells.
Iseki Y; Imoto A; Okazaki T; Harigae H; Takahashi S
Leuk Res; 2009 Dec; 33(12):1658-63. PubMed ID: 19428102
[TBL] [Abstract][Full Text] [Related]
15. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
[TBL] [Abstract][Full Text] [Related]
16. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
17. PU.1 can regulate the ZNF300 promoter in APL-derived promyelocytes HL-60.
Xu JH; Wang T; Wang XG; Wu XP; Zhao ZZ; Zhu CG; Qiu HL; Xue L; Shao HJ; Guo MX; Li WX
Leuk Res; 2010 Dec; 34(12):1636-46. PubMed ID: 20471086
[TBL] [Abstract][Full Text] [Related]
18. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous deletion of the PU.1 locus in human AML.
Bonadies N; Pabst T; Mueller BU
Blood; 2010 Jan; 115(2):331-4. PubMed ID: 19890096
[TBL] [Abstract][Full Text] [Related]
20. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Giles FJ
Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
